2020
DOI: 10.1590/1806-9282.66.s1.45
|View full text |Cite
|
Sign up to set email alerts
|

Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives

Abstract: INTRODUCTION: Acute kidney injury (AKI) is highly prevalent today. It has a multifactorial aetiology and affects people of all ages, genders and ethnicities. Its treatment is essentially supportive of renal function substitution, so new treatment alternatives such as mesenchymal stem cell therapy (MSCs) should be investigated. METHODS: This review encompasses our understanding of the main mechanisms of action of MSCs in preclinical models of AKI by renal pedicle clamping ischemia-reperfusion, chemotherapy (cis… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
24
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 30 publications
(26 citation statements)
references
References 41 publications
1
24
0
1
Order By: Relevance
“…Either due to their antiapoptotic, neoangiogenic, or immunomodulatory effects, MSC has demonstrated to exert protective actions in several cardiovascular diseases [ 54 56 ]. Similar effects of MSC and their EVs (extracellular vesicles) have been reported in acute kidney injury models [ 57 ]. The liver has also been reported to be injured during COVID-19, mainly by cholestasis and hepatitis [ 58 ].…”
Section: Stem Cell Therapies For Covid-19supporting
confidence: 61%
“…Either due to their antiapoptotic, neoangiogenic, or immunomodulatory effects, MSC has demonstrated to exert protective actions in several cardiovascular diseases [ 54 56 ]. Similar effects of MSC and their EVs (extracellular vesicles) have been reported in acute kidney injury models [ 57 ]. The liver has also been reported to be injured during COVID-19, mainly by cholestasis and hepatitis [ 58 ].…”
Section: Stem Cell Therapies For Covid-19supporting
confidence: 61%
“…MSC-based therapy is a promising strategy for accelerating kidney recovery, repairing and regenerating tissue damage after acute injury following ischemia-reperfusion, kidney transplant, and drug-mediated toxicity, as reviewed elsewhere [ 55 ]. In a meta-analysis including MSC from rat and mice (~200 animals treated) and different types of acute and chronic kidney injury (but not DKD), routes of delivery (intravenous, intrarenal, intraperitoneal, and intra-arterial), and MSC number (range, 7.5 × 10 4 ‐3.0 × 10 6 ), the beneficial outcomes for kidney recovery favored MSC treatment [ 56 ].…”
Section: Mesenchymal Stem Cells (Mscs)mentioning
confidence: 99%
“…O primeiro paciente, apresentava uma concentração sérica de creatinina classificada no estágio 4 (5,76 mg/dL) e era submetido a procedimentos de fluídoterapia subcutânea por pelo menos três vezes por semana, além de se alimentar via sonda esofágica a mais de 30 dias. Foi Esses resultados vão de encontro ao encontrado em um estudo recente, o qual concluiu que a terapia com CTM é muito promissora e pode retardar a progressão da DRC (SILVA et al, 2020).…”
Section: Resultsunclassified